Consensus $57.94M. "Despite a difficult macroeconomic environment, our shift to a product-led operating structure is already yielding positive results," said Cardlytics CEO Karim Temsamani. "Our improved topline guidance is driven by better than expected growth in the US business and the product optimizations discussed on our last earnings call. Additionally, our rigorous approach in managing our cost structure, including implementing $3.5 million of one-time savings during the first quarter, has positioned the business to exceed the high end of our previously announced Adjusted EBITDA range. We are confidently navigating 2023 and look forward to sharing more positive updates over the coming months."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDLX:
- Cardlytics Announces Updated Guidance for First Quarter 2023 Financial Results
- Cardlytics CFO Andy Christiansen to resign
- Cardlytics Announces CFO Transition
- Cardlytics Announces Partial Drawdown of Line of Credit in Response to Uncertainty in the Financial Sector
- Cardlytics price target lowered to $8 from $14 at Needham